Tebentafusp’s OS Benefit in Uveal Melanoma Holds Up at 3 Years
MADRID — The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of a phase III trial demonstrated. In HLA-A*02:01-positive patients, landmark analyses showed improved overall survival (OS) at 1, 2, and 3 years with tebentafusp versus […]
New Data on BCMA-Directed Bispecifics in Multiple Myeloma
Promising data on new B-cell maturation antigen (BCMA)-directed bispecific antibodies were presented at the American Society of Clinical Oncology (ASCO) annual meeting. These included results on two investigational products: the phase II LINKER-MM1 study, which showed that linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with […]
Bispecific Antibody Shows Promise in R/R Multiple Myeloma
Teclistamab, a bispecific antibody that binds B-cell maturation antigen (BCMA) and CD3 to redirect T cells to multiple myeloma cells, showed promising efficacy in patients with relapsed or refractory disease, according to results from a phase I study. Forty patients received the recommended phase II dose of subcutaneous teclistamab, which led to an overall response […]